SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after reporting robust earnings and strong guidance driven by its booming data center and AI segments, yet community discussion is polarized between long-term bullish conviction in its AI leadership and concerns over the muted stock reaction, high valuation, and options expiring worthless amid perceived market manipulation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as the community celebrates a significant earnings and revenue beat, fueling expectations of continued growth driven by the Alani Nu acquisition and expanding PepsiCo partnership. Investors are actively discussing the potential for the stock to be "Monster 2.0" and reach new highs as it gains substantial shelf space.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors eagerly await its upcoming earnings report for crucial updates on the AUR200 pipeline, with extensive community discussion fueled by ongoing frustration with management's communication and heightened speculation of a potential acquisition.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending after delivering financial results that significantly surpassed expectations, fueling community discussion about a potential short squeeze and the strategic implications of its recent SkyWater acquisition. The market is actively debating its strong revenue growth and ambitious quantum computing roadmap against continuing profitability challenges.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending after its earnings report delivered a revenue and EPS beat, but its weaker-than-expected Q1 guidance triggered a significant share price decline and a Loop Capital downgrade. Community sentiment is split, with many investors decrying perceived management missteps and market manipulation, while others view the substantial dip as an attractive entry point for a fundamentally sound, oversold company.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is seeing intense debate ahead of its Q4 earnings report, with bullish investors anticipating significant growth from new large-scale project wins and the surging demand for grid-scale energy storage, particularly for AI data centers, while others remain wary of past performance.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is intensely discussed ahead of its earnings report, with optimism fueled by recent government and enterprise contract wins, coupled with the CEO's claims of immediate real-world applications for its dual-platform quantum technology, particularly in defense. However, community debate persists regarding the stock's high valuation and the quantum sector's timeline to consistent profitability.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce (CRM) is trending after exceeding earnings expectations and announcing a significant new share repurchase program, sparking a tug-of-war between bulls who see deep value and future EPS growth, and bears concerned about long-term growth prospects amidst pervasive AI disruption fears in the software sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending due to its ANKTIVA's expanded European access and global approvals for bladder cancer, coupled with strong clinical data and 700% year-over-year revenue growth. The community is buzzing about a recent significant pullback, debating whether it's a buying opportunity or a "bear trap" for shorts, given the high short interest and the founder's reaffirmed majority control.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after its Friedreich's ataxia drug, nomlabofusp, received FDA Breakthrough Therapy Designation, leading to a significant rally followed by an upsized $100 million stock offering at $5 per share. Bulls are excited about the accelerated approval pathway and potential blockbuster status, citing analyst upgrades and anticipating a short squeeze, while bears emphasize dilution concerns, the company's lack of revenue, and high debt.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +219.14% and +2.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Director Sells 10,349 Shares of Stock

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,349 shares of the company's stock in a transaction on Monday, February 2nd. The stock was sold at an...

Fennec Pharmaceuticals (TSE:FRX) Upgraded to Strong-Buy at B.Riley Securit

B.Riley Securit raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday...

Adherex Technologies (NASDAQ:FENC) Upgraded at B.Riley Securit

B.Riley Securit raised Adherex Technologies to a "strong-buy" rating in a research note on Wednesday...

Adherex Technologies (NASDAQ:FENC) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded Adherex Technologies from a "buy" rating to a "strong-buy" rating in a research report on Saturday...

Adherex Technologies (NASDAQ:FENC) Now Covered by B. Riley Securities

B. Riley Securities initiated coverage on Adherex Technologies in a report on Thursday. They issued a "buy" rating and a $16.00 target price on the stock...

Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below Fifty Day Moving Average - Here's What Happened

Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below Fifty Day Moving Average - What's Next...

Fennec Pharmaceuticals (TSE:FRX) Stock Crosses Below Fifty Day Moving Average - Here's What Happened

Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Below 50-Day Moving Average - Here's Why...

Rosty Raykov Sells 10,349 Shares of Adherex Technologies (NASDAQ:FENC) Stock

Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,349 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at an...

Fennec Pharmaceuticals (TSE:FRX) Insider Southpoint Capital Advisors Lp Sells 1,000,000 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Southpoint Capital Advisors Lp sold 1,000,000 shares of Fennec Pharmaceuticals stock in a transaction dated Wednesday, December 24th...

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Current Price	$8.87
Prev Close	$8.91
Open	$8.94
Dividend Yield	0.00%
50-Day Moving Average	$7.84
Beta	0.88
Avg. Volume	116,180.05
PE Ratio	-37.44

52-Week High	$9.92
52-Week Low	$4.68
Market Capitalization	$304.19M
EPS (Annual)	-$0.016
Price to Book	-55.66
Revenue Per Employee	$1.49M

FENC
Fennec Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FENC News

FENCFennec Pharmaceuticals Inc